Followers | 145 |
Posts | 27566 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Monday, August 01, 2022 7:51:12 AM
Aug. 01, 2022 7:21 AM ETGamida Cell Ltd. (GMDA)
By: Ravikash, SA News Editor
The U.S. Food and Drug Administration (FDA) granted priority review to Gamida Cell's (NASDAQ:GMDA) application seeking approval of stem cell therapy omidubicel to treat patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.
The FDA accepted the company's Biologics License Application (BLA) and is expected to make a decision by Jan. 30, 2023.
Under priority review, the FDA's goal is to take action within six months,
compared to 10 months under standard review.
Gamida said the FDA is not planning to hold an Advisory Committee
meeting as part of the BLA review.
The company noted that the BLA was backed by data from a phase 3 trial.
Upon FDA approval, omidubicel will be manufactured at the Gamida's manufacturing facility in Israel, the company added.
Recent GMDAQ News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/10/2024 08:19:25 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/09/2024 08:08:28 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/09/2024 08:04:39 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM